Media Highlights and Announcements

With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.

Learn More

Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.

Learn More

Crawley-based Artrya has been shortlisted as a preferred supplier of AI Software by the UK Health Service for its heart disease detection program.

Learn More

In this article, the Financial Review shares some information on our accomplishments, IPO and overall progress towards our goals.

Learn More

After closing our initial public offering (IPO), the Motley Fool shares details on Artrya’s AI technology and how it could disrupt the detection of coronary artery disease for years to come.

Learn More

Amid a biotech boom, see how Artrya, an aussie medtech company, is pioneering the detection and assessment of the underlying cause of heart attack.

Learn More

Artrya’s co-founder and Managing Director, John Barrington AM, recently took part in a Q&A with Stockhead.

Learn More

Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange.

Learn More

We’re proud to be acknowledged in Signify Research’s Product Developments & Technology Trends report.

Learn More

Business NewsJune 21, 2021

Researchers Eye Health Benefit From AI

Several exciting AI innovations are emerging from WA, and the world is watching.

Learn More